1型糖尿病(若年性糖尿病)治療薬のグローバル製品開発パイプライン動向

◆英語タイトル:Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014
◆商品コード:GMDHC5663IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2014年10月30日
◆ページ数:511
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2014’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 1 Diabetes (Juvenile Diabetes) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Type 1 Diabetes (Juvenile Diabetes) Overview 8
Therapeutics Development 9
Type 1 Diabetes (Juvenile Diabetes) – Therapeutics under Development by Companies 11
Type 1 Diabetes (Juvenile Diabetes) – Therapeutics under Investigation by Universities/Institutes 20
Type 1 Diabetes (Juvenile Diabetes) – Pipeline Products Glance 22
Type 1 Diabetes (Juvenile Diabetes) – Products under Development by Companies 26
Type 1 Diabetes (Juvenile Diabetes) – Products under Investigation by Universities/Institutes 38
Type 1 Diabetes (Juvenile Diabetes) – Companies Involved in Therapeutics Development 40
Type 1 Diabetes (Juvenile Diabetes) – Therapeutics Assessment 135
Drug Profiles 147
Type 1 Diabetes (Juvenile Diabetes) – Recent Pipeline Updates 400
Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects 476
Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products 479
Type 1 Diabetes (Juvenile Diabetes) – Product Development Milestones 480
Appendix 489



【掲載企業】

4SC AG
ActogeniX NV
Adocia
Ambrx, Inc.
American Gene Technologies International Inc.
AntriaBio, Inc.
Aphios Corporation
Argos Therapeutics, Inc.
Artery Therapeutics, Inc.
AstraZeneca PLC
Axxam SpA
Bayhill Therapeutics, Inc.
Beta-Cell NV
Biocon Limited
Biodel Inc.
Biogenomics Limited
BioLineRx, Ltd.
BioTherapeutics Inc.
Boehringer Ingelheim GmbH
Cebix Incorporated
Cellectis S.A.
Compugen Ltd.
Coronado Biosciences, Inc.
Cortendo AB
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Dance Pharmaceuticals
Diabetology Limited
DiaMedica Inc.
Dompe Farmaceutici S.p.A.
DoNatur GmbH
Eli Lilly and Company
EpiVax, Inc.
Escape Therapeutics, Inc.
Evotec AG
Exsulin Corporation
Extrawell Pharmaceutical Holdings Limited
Flamel Technologies S.A.
Generex Biotechnology Corporation
GeNeuro SA
Gilead Sciences, Inc.
GlaxoSmithKline plc
Grifols, S.A.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Immunocore Limited
Inovio Pharmaceuticals, Inc.
Intrexon Corporation
Islet Sciences, Inc.
Johnson & Johnson
Kamada Ltd.
Kasiak Research Pvt. Ltd.
Kineta, Inc.
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
Ligand Pharmaceuticals, Inc.
MacroGenics, Inc.
Medestea Research & Production S.p.A.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Mertiva AB
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
NasVax Ltd.
NeoStem, Inc.
NGM Biopharmaceuticals, Inc.
Novo Nordisk A/S
Noxxon Pharma AG
Omni Bio Pharmaceutical Inc.
Opexa Therapeutics, Inc.
Oramed Pharmaceuticals, Inc.
Orgenesis, Inc.
Paras Biopharmaceuticals Finland Oy
Pathfinder Cell Therapy, Inc.
Pfizer Inc.
PharmaIN Corporation
PlasmaTech Biopharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Provid Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
REGiMMUNE Corporation
RhinoCyte, Inc.
Sanofi
SEKRIS Biomedical, Inc.
Selecta Biosciences, Inc.
Thermalin Diabetes, LLC
Toleranzia AB
Transgene Biotek Limited
Uni-Bio Science Group Ltd.
ViaCyte, Inc.
X-BODY BioSciences, Inc.
XL-protein GmbH
XOMA Corporation

【レポートのキーワード】

1型糖尿病(若年性糖尿病)、治療薬、薬剤、開発開発、製薬企業、製品パイプライン

★調査レポート[1型糖尿病(若年性糖尿病)治療薬のグローバル製品開発パイプライン動向] (コード:GMDHC5663IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[1型糖尿病(若年性糖尿病)治療薬のグローバル製品開発パイプライン動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆